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ABSTRACT
Objective To develop and validate version two of the
QRISK cardiovascular disease risk algorithm (QRISK2) to
provide accurate estimates of cardiovascular risk in
patients from different ethnic groups in England and
Wales and to compare its performance with the modified
version of Framingham score recommended by the
National Institute for Health and Clinical Excellence
(NICE).
Design Prospective open cohort study with routinely
collected data from general practice, 1 January 1993 to
31 March 2008.
Setting 531 practices in England and Wales contributing
to the national QRESEARCH database.
Participants 2.3 million patients aged 35-74 (over
16 million person years) with 140000 cardiovascular
events. Overall population (derivation and validation
cohorts) comprised2.22millionpeoplewhowerewhite or
whose ethnic group was not recorded, 22013 south
Asian, 11595 black African, 10402 black Caribbean, and
19792 fromChineseor other Asianor other ethnic groups.
Main outcome measures First (incident) diagnosis of
cardiovascular disease (coronary heart disease, stroke,
and transient ischaemic attack) recorded in general
practice records or linked Office for National Statistics
death certificates. Risk factors included self assigned
ethnicity, age, sex, smoking status, systolic blood
pressure, ratio of total serum cholesterol:high density
lipoprotein cholesterol, bodymass index, family history of
coronary heart disease in first degree relative under
60 years, Townsend deprivation score, treated
hypertension, type 2 diabetes, renal disease, atrial
fibrillation, and rheumatoid arthritis.
Results The validation statistics indicated that QRISK2
had improved discrimination and calibration compared
with the modified Framingham score. The QRISK2
algorithm explained 43% of the variation in women and
38% in men compared with 39% and 35%, respectively,
by the modified Framingham score. Of the 112156
patients classified as high risk (that is, ≥20% risk over
10 years) by the modified Framingham score, 46094
(41.1%)would be reclassified at low riskwithQRISK2. The
10 year observed risk among these reclassified patients
was 16.6% (95% confidence interval 16.1% to 17.0%)—
that is, below the 20% treatment threshold. Of the 78024
patients classified at high risk onQRISK2, 11962 (15.3%)
would be reclassified at low risk by the modified
Framinghamscore. The10yearobserved riskamong these
patients was 23.3% (22.2% to 24.4%)—that is, above the
20% threshold. In the validation cohort, the annual
incidence rate of cardiovascular events among those with
a QRISK2 score of ≥20% was 30.6 per 1000 person years
(29.8 to 31.5) for women and 32.5 per 1000 person years
(31.9 to 33.1) for men. The corresponding figures for the
modified Framingham equation were 25.7 per 1000
person years (25.0 to 26.3) for women and 26.4 (26.0 to
26.8) for men). At the 20% threshold, the population
identified by QRISK2 was at higher risk of a CV event than
the population identified by the Framingham score.
Conclusions Incorporating ethnicity, deprivation, and
other clinical conditions into the QRISK2 algorithm for risk
of cardiovascular disease improves the accuracy of
identification of those at high risk in a nationally
representative population. At the 20% threshold, QRISK2
is likely to be a more efficient and equitable tool for
treatment decisions for the primary prevention of
cardiovascular disease. As the validation was performed
in a similar population to the population from which the
algorithm was derived, it potentially has a “home
advantage.” Further validation in other populations is
therefore advised.
INTRODUCTION
Cardiovascular disease is the leading cause of pre-
mature death and a major cause of disability in the
United Kingdom.1 Evidence from randomised con-
trolled trials supports the effectiveness of statins in
reducing cardiovascular risk and theNational Institute
forHealth andClinicalExcellence (NICE)has lowered
the threshold for intervention for primary prevention
with statins from a 10 year risk of cardiovascular
disease of 40% to 20%.23 In April 2008, the UK
government announced a new major initiative to
reduce the risk of vascular disease.4 This will build on
new NICE guidelines for lipid modification to be
published later this year.5 It is important that thismajor
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public health programme targets those at greatest risk
and reduces, rather than exacerbates, existing persis-
tent and widening ethnic and social inequalities in risk
of cardiovascular disease.6-8 A broader approach to
preventative cardiovascular medicine is required that
recognises the evidence for the role of the biological,
socioeconomic, and ethnic determinants of health910
and is responsive to changes in secular trends in the
incidence of coronary heart disease.11
Recent advances in the development of models to
assess risk of cardiovascular disease means these can
now recognise and take account of the increased risk
associated with social deprivation in the UK.12 13 Rates
of cardiovascular disease, however, vary considerably
between ethnic groups, which might reflect increased
susceptibility and differential exposure to risk
factors.14-17While several riskprediction scoresderived
from prospective studies can be used to identify and
prioritise people for risk reducing interventions,12 13 18
they do not include a variable for self assigned
ethnicity. One cross sectional study used ethnicity
specific levels of risk of cardiovascular disease and risks
factors to estimate 10 year risk. The use of this tool,
however, excluded diabetes, lacked precision because
of small numbers, and has not been validated.19
In May 2008, NICE recommended multiplying the
results of a modified version of the US Framingham
score (“modified Framingham”) by a correction factor
of 1.4 for south Asian men in the UK.5 This does not
reflect the heterogeneity in risk of cardiovascular
disease between south Asian populations, the
increased risk in women, confounding by
deprivation,20 and the possibility of double counting
through adjustments for both ethnicity and family
history. An appropriate estimation of risk by ethnic
group is important to improve cardiovascular out-
comes, avoid the potential for further deterioration in
health inequalities,21 and ensure the efficient allocation
of resources used to support cardiovascular disease
prevention programmes.
Because of the lack of prospective outcome data on
black and minority ethnic groups,22 a contemporary
and specific algorithm is needed to accurately quantify
risk among such patients and to identify the indepen-
dent or interacting contributions of factors including
deprivation, family history, and diabetes.23-25 The
QRESEARCH database contains longitudinal data,
individual risk factors, demographic data, measures of
social deprivation, and, increasingly, records of self
assigned ethnicity, which provide a unique opportu-
nity to model all these factors together.
We built on our previous risk prediction algorithm
(QRISK1)12 to develop a revised algorithm that
incorporates self assigned ethnicity as well as a range
of other potentially relevant conditions associatedwith
cardiovascular risk such as type 2 diabetes, treated
hypertension, rheumatoid arthritis, renal disease, and
atrial fibrillation (QRISK2). By including an increased
range of potential risk factors, we hypothesised that we
would be better able to personalise risk to the
individual patient.
METHODS
Study design and data source
Weconducted aprospective cohort study in a largeUK
primary care population using a similar method to our
original analysis.12 We used version 19 of the
QRESEARCH database (www.qresearch.org). This is
a large validated primary care electronic database
containing the health records of 11 million patients
registered from 551 general practices using the Egton
Medical Information System (EMIS) computer
system.12 Practices and patients on the database are
nationally representative26 and similar to those on
other primary care databases that use other clinical
software systems.27
The QRESEARCH database now contains informa-
tion on the cause of death as recorded on the patient’s
Office for National Statistics (ONS) death certificate.
This data linkage, which is based on NHS number, has
now been successfully completed back to 1993. A
recorded cause of death is now linked for over 97% of
patients on theQRESEARCHdatabasewhohavedied.
Practice selection
We included all QRESEARCH practices in England
andWales once theyhadbeen using their current EMIS
system for at least a year (to ensure completeness of
recording ofmorbidity and prescribing data), randomly
allocating two thirds of practices to the derivation
dataset with one third to the validation dataset.We used
the simple random sampling utility in Stata to assign
practices to the derivation or validation cohort.
Cohort selection
We identified an open cohort of patients aged 35-74 at
the study entry date, drawn from patients registered
with eligible practices during the 15 years from
1 January 1993 to 31 March 2008. We used an open
cohort design as this allows patients to enter the
population throughout the whole study period rather
than requiring registration on 1 January 1993, thus
better reflecting the realities of routine general practice.
We excluded patients with a prior recorded diag-
nosis of cardiovascular or cerebrovascular disease,
temporary residents, patients with interrupted periods
of registration with the practice, and those who did not
have a valid Townsend deprivation score. We also
excluded patients who were taking statins at baseline.
For each patient we determined an entry date to the
cohort, which was the latest of the following dates:
35th birthday, date of registration with the practice,
date on which the practice computer system was
installed plus one year, and the beginning of the study
period (1 January 1993). In addition we included
patients in the analysis only once they had a minimum
of one year’s complete data in their medical record.
Coding of ethnicity
We used Read codes for self assigned ethnicity.
The codes were grouped into the NHS standard
16+1 categories28 for the initial descriptive analysis.
The 16+1 categories were then further grouped into the
RESEARCH
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final nine reporting groups to ensure sufficient numbers
of events to enable a meaningful analysis. The white
ethnic group was combined with the group where
ethnicity was not recorded since, assuming the study
population is comparable with theUKpopulation, 93%
or more of people without ethnicity recorded would be
expected to be from awhite ethnic group. The category
“other including mixed” comprised white and black
Caribbean, white and black African, white and Asian,
other mixed, other black, and other ethnic group. The
“white or not recorded” category comprised British,
Irish, and other white background as well as not
recorded.Thiswasdesignatedas the reference category.
The category of other Asian included Read codes for
east AfricanAsian, Indo-Caribbean, Punjabi, Kashmiri,
Sri Lankan, Tamil, Sinhalese, Caribbean Asian, British
Asian, mixed Asian, or Asian unspecified.
Cardiovascular disease outcomes
The primary outcome measure was the first recorded
diagnosis of cardiovascular disease recorded on the
general practice clinical computer system or their
linked ONS death certificate during the study period.
For this study, we included coronary heart disease
(angina andmyocardial infarction), stroke, or transient
ischaemic attacks in the term cardiovascular disease
but not peripheral vascular disease.
The Read codes used for case identification on the
computer record were nationally agreed ones used in
the quality and outcomes framework for general
practice for coronary heart disease and cerebrovascular
disease. The ICD-10 codes used for case identification
on theONSdeath certificatewere: anginapectoris (I20);
acutemyocardial infarction (I22); complications follow-
ing acute myocardial infarction (I23); other acute
ischaemic heart disease (I24); chronic ischaemic heart
disease (I25); cerebral infarction (I63); and stroke, not
specified as haemorrhage or infarction (I64).
Risk factors for cardiovascular disease
Weincludedvariables inour analysis that are knownor
thought to affect cardiovascular risk (box).Weused the
value closest to the entry date to the cohort for each
patient, imputing missing values where necessary, as
described below.
Model derivation and development
We calculated crude incidence rates of cardiovascular
disease according to age, ethnic group, anddeprivation
in fifths. We directly age standardised the incidence
rates by ethnic group and deprivation using the age
distribution in five year bands of the entire derivation
cohort as the standard population. We also age
standardised the means of continuous variables and
proportions with risk factors by ethnic group using the
same method.
We used Cox proportional hazards models in the
derivation dataset to estimate the coefficients and
hazard ratios associated with each potential risk factor
for the first ever recorded diagnosis of cardiovascular
disease for men and women separately. As in our
previous paper, we compared models using the
Bayesian information criteria (BIC).33 We used frac-
tional polynomials to model non-linear risk relations
with continuous variables where appropriate.34 35 We
tested for interactions between each variable and age
and between diabetes and deprivation and included
significant interactions in the final model. Continuous
variables were centred for analysis.
Our main analyses used multiple imputation to
replace missing values for systolic blood pressure,
cholesterol/HDL ratio, smoking status, and body mass
index. Our final model was fitted based on multiply
imputed datasets using Rubin’s rules to combine effect
estimates and estimate standard errors to allow for the
uncertainty caused by missing data.3536 Multiple impu-
tation is a statistical technique designed to reduce the
biases that can occur in “complete case” analysis along
with a substantial loss of power and precision.37-40
Multiple imputation allows patients with incomplete
data to still be included in analyses andmakes full use of
all the available data, increasing power and precision.41
The imputation technique involves creating multiple
copies of the data and replaces missing values with
imputedvaluesbasedona suitable randomsample from
theirpredicteddistribution.Weused the ICEprocedure
in Stata42 to obtain five imputed datasets (further details
are available from the corresponding author).
We took the log of the hazard ratio for each variable
from the final model and used these as weights for the
new cardiovascular disease risk equations. We com-
bined theseweights with the baseline survivor function
centred on the means of continuous risk factors to
derive a risk equation for 10 years’ follow-up.
Validation of new equation
Wetested the performanceof the newmodel (QRISK2)
in the validation dataset and compared it against both
the original model (QRISK1) and the modified
Framingham equation recommended by NICE.43 This
Included variables
 Selfassignedethnicity (white/not recorded, Indian,Pakistani,Bangladeshi,otherAsian,
black African, black Caribbean, Chinese, other including mixed)
 Age (years)
 Sex (males v females)
 Smoking status (current smoker, non-smoker (including ex-smoker))
 Systolic blood pressure18 (continuous)
 Ratio of total serum cholesterol/high density lipoprotein cholesterol18 (continuous)
 Body mass index (BMI)12 (continuous)
 Family history of coronary heart disease in first degree relative under 60 years12 (yes/no)
 Townsend deprivation score12 (output area level 2001 census data evaluated as a
continuous variable)
 Treated hypertension12 (diagnosis of hypertension and at least one current prescription
of at least one antihypertensive agent)
 Rheumatoid arthritis29 (yes/no)
 Chronic renal disease30 (yes/no)
 Type 2 diabetes18 (yes/no)
 Atrial fibrillation3132 (yes/no)
RESEARCH
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modified equation is based on one of the original
Anderson equations18 and is used to derive separate
risks for coronary heart disease and stroke for an
individual. The two risks are then added together (if
these combined risks exceed100%, the risk is then set to
100%). For southAsianmen,NICEadvisesmultiplying
the resulting Framingham score by 1.4. For people with
a familyhistoryofcoronaryheartdisease ina firstdegree
relative, then the risk is multiplied by 1.5. For south
Asian men with a family history of coronary heart
disease both multipliers are applied to the individual.
We calculated the 10 year estimated risk of cardio-
vascular disease for each patient in the validation
dataset using multiple imputation to replace missing
values as in the derivation dataset.
We calculated the mean predicted and observed
cardiovascular disease risk at 10 years12 and compared
these by 10th of predicted risk for each score. The
observed risk at 10 years was obtained by using the
10 year Kaplan-Meier estimate. We calculated the
Brier score (a measure of goodness of fit where lower
values indicate better accuracy)44 using the censoring
adjusted version adapted for survival data,45 D statistic
(a measure of discrimination where higher values
indicate better discrimination),46 and an R2 statistic.
The R2 statistic is a measure of explained variation
where higher values indicate more explained
variation.47 We also calculated the area under the
receiver operator curve (ROC), where higher values
indicate better discrimination.
We calculated the proportion of patients in the
validation sample with an estimated 10 year risk of
cardiovascular disease of 20% or more by age, sex,
ethnicity, and deprivation according to the QRISK2
algorithm compared with the modified Framingham
score. We determined the proportion of patients who
would be reclassified into a higher or lower risk
category using the new risk equations at the 20%
thresholds and determined the observed 10 year risks
among those patients who would be reclassified.
As we used all the available data on the QRE-
SEARCH database we did not calculate required
sample size before the study. Analyses were conducted
usingStata (version10),with a significance level of 0.01
(two tailed).
RESULTS
Derivation and validation datasets
Practices and patients
Overall, 531 UK practices met our inclusion criteria, of
which 355 were randomly assigned to the derivation
datasetand176 to thevalidationdataset.Weexcluded20
practices that did nothave completedata for the relevant
study period (four practices) or were from Scotland
(seven practices) or Northern Ireland (nine practices).
We studied2.29millionpatientswithover 16million
person years and 140 115 cardiovascular events. There
were 1 591 209 patients in the derivation cohort, of
whom 55 626 had cardiovascular disease before the
start of the study leaving 1 535 583 patients (773 291
women, 50.4%) aged 35-74 and free of cardiovascular
disease. Table 1 shows the numbers of patients in each
ethnic group.
Baseline characteristics of derivation and validation
cohort
Table 1compares the characteristics of eligiblepatients
in both cohorts. Ethnicity was recorded in 209 214
(27.1%) women and 181 110 (23.8%) men. Among
patients with ethnicity recorded 89.3% were from a
white ethnic group. The mean follow-up was 7.3 years
for women and 6.9 for men. Some 437 676 patients
(232 306 women and 205 370 men) had more than
10 years of follow-up data.
While this validation cohort was drawn from an
independent group of practices, the baseline character-
istics were similar to those for the derivation cohort.
Incidence of cardiovascular disease
Table 2 shows the incidence rates of cardiovascular
disease by age, sex, deprivation, and ethnicity in the
derivation cohort. There were 96 709 incident cases of
cardiovascular disease (41 042 in women) during the
study period from 10.9 million person years of observa-
tion.Of all events, 7.4% inwomenand7.8% inmenwere
identified with the ONS linked death data (that is, were
not identified with the general practice data alone). The
crude incidence rate for cardiovascular disease was
slightlyhigher than inouroriginal studywith a rate of 7.3
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Fig 1 | Impact of age on hazard ratios for cardiovascular disease
risk factors using the QRISK2 model
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per 1000 person years for women and 10.5 per 1000
personyears formen. In thevalidationdataset therewere
750232 eligible patients aged 35 to 74, and, of these,
50.1%were women and the incidence rates were similar
to the derivation dataset (data not shown, but available
from the corresponding author).
The incidence of crude and age standardised cardio-
vascular disease varied widely between ethnic groups
(table2).Theagestandardisedrates for thewhitereference
group were 10.5 per 1000 person years (95% confidence
interval 10.4 to 10.6) for men and 7.3 per 1000 person
years (7.2 to7.3) forwomen.Thehighest age standardised
rates were among south Asians groups—for example, for
Bangladeshi people the rate was 24.4 per 1000 person
years (19.8 to 29.0) for men and 11.3 per 1000 person
years (8.5 to14.1) forwomen.Agestandardisedrateswere
also high for Indian and Pakistani men and women
comparedwith thewhite referencegroup.Theywere also
higher for black Caribbean women and men from the
“other Asian” group. In contrast, black African, Chinese,
and black Caribbean men tended to have lower rates, as
did black African women (table 2).
Characteristics of events
Table 3 shows the characteristics of events amongmen
and women by ethnic group. Overall, 30.8% of events
were stroke or transient ischaemic attacks, but this
varied between ethnic groups. For example in the
derivation dataset, 48.9% of first events among black
Caribbean men and 36.4% among black African men
were stroke or transient ischaemic attacks; the corre-
sponding figures for women were 33.5% and 24.2%.
Prevalence of risk factors by ethnicity
Table 4 shows the distribution of risk factors, standar-
dised for age, among each of the main ethnic groups.
There was substantial heterogeneity across the ethnic
groups in risk factors for cardiovascular disease and this
also differed betweenmen and women within an ethnic
group. The notable results include differences in the age
standardised prevalence of smoking among men of
Bangladeshi (53.2%, 50.2% to 56.2%), Caribbean
(40.6%, 38.9% to 42.4%), Pakistani (32.9%, 30.8% to
35.1%), white/not recorded (32.2%, 32.1% to 32.3%),
Chinese (28.0%, 24.6% to 31.4%), Indian (23.7%, 22.3%
to 25.1%), and black African (16.6%, 15.1% to 18.2%)
origin. Current smoking rates were all lower for women
in each ethnic group compared with men but varied
widely between women from different groups.
There were also substantial differences in the age
standardised prevalence of type 2 diabetes between
ethnic groups with highest rates among Bangladeshis
Table 1 | Characteristics of patients aged 35-74 in derivation and validation cohorts in QRESEARCH database (version 19)
1993-2008
Derivation cohort Validation cohort
No (%) of women No (%) of men No (%) of women No (%) of men
No of patients 773 291 762 292 375 763 374 469
Total person years observation 5 645 104 5 280 571 2 594 842 2 470 729
Median age (IQR) 49 (41-60) 48 (40-58) 49 (41-59) 47 (40-57)
Ethnicity:
White or not recorded 752 241 (97.3) 743 159 (97.5) 363 516 (96.7) 363 097 (97.0)
Indian 3635 (0.47) 3693 (0.48) 2241 (0.60) 2200 (0.59)
Pakistani 2035 (0.26) 2033 (0.27) 1114 (0.30) 1246 (0.33)
Bangladeshi 1213 (0.26) 1269 (0.17) 611 (0.16) 723 (0.19)
Other Asian 1802 (0.16) 1422 (0.19) 1086 (0.29) 988 (0.26)
Black Caribbean 3928 (0.51) 3109 (0.41) 1870 (0.50) 1495 (0.40)
Black African 3655 (0.47) 3316 (0.44) 2423 (0.64) 2201 (0.59)
Chinese 1128 (0.15) 859 (0.11) 675 (0.18) 478 (0.13)
Other including mixed 3654 (0.47) 3432 (0.45) 2227 (0.59) 2041 (0.55)
Risk factors:
Ethnicity recorded 209 214 (27.1) 181 110 (23.8) 108 540 (28.9) 94 522 (25.2)
BMI recorded 622 741(80.5) 562 278 (73.8) 304 084 (80.9) 274 403 (73.3)
Smoking recorded 703 574 (91.0) 650 460 (85.3) 344 194 (91.6) 319 800 (85.4)
Cholesterol/HDL ratio recorded 265 402 (34.3) 247 116 (32.4) 210 638 (56.1) 125 037 (33.4)
Systolic blood pressure recorded 711 935 (92.1) 647 782 (85.0) 344 967 (91.8) 313 125 (83.6)
Complete BMI and smoking 615 301 (79.6) 554 070 (72.7) 301 016 (80.1) 270 956 (72.4)
Positive family history of CHD 97 448 (12.6) 73 740 (9.7) 48 610 (12.9) 36 761 (9.8)
Current smoker 176 202 (22.8) 208 913 (27.4) 88 672 (23.6) 104 829 (28.0)
Treated hypertension 55 069 (7.12) 42 607 (5.59) 25 953 (6.91) 20 083 (5.36)
Type 2 diabetes 13 127 (1.70) 17 107 (2.24) 6186 (1.65) 8179 (2.18)
Rheumatoid arthritis 7187 (0.93) 2996 (0.39) 3310 (0.88) 1380 (0.37)
Atrial fibrillation 2692 (0.35) 1880 (0.25) 1242 (0.33) 2155 (0.58)
Chronic kidney disease 1227 (0.16) 1117 (0.15) 621 (0.17) 498 (0.13)
IQR=interquartile range; BMI=body mass index; HDL=high density lipoprotein cholesterol; CHD=coronary heart disease.
RESEARCH
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(14.4% women, 16.8% men), Pakistanis (14.2%
women, 12.0% men), and Indians (11.7% women,
13.3% men) and lowest among the white reference
group (1.5% women, 2.1% men).
Treated hypertensionwas highest amongCaribbean
and black African men and women. Recorded family
history of coronary heart disease in a first degree
relative was highest among Indian men and women
and lowest among black African men and women.
Model development
Table 5 shows the results of theCox regression analysis
for the QRISK2 model. We used a log transformation
for age but otherwise fitted variables as linear terms as
this provided a better fit with the data according to the
fractional polynomial analysis. The table shows vari-
ables that had significant interactions with age and
these indicate increased hazard ratios for the risk
factors among younger patients compared with older
patients (fig 1).
Calibration and discrimination of QRISK2
The QRISK2 model was marginally superior to the
original QRISK1 equation and both models were
superior to the modification of the Framingham score
for the D statistic, ROC statistic, and the R2 value—for
both men and women (table 6). For example, the
QRISK2 algorithm explained 43% of the variation in
women and 38% in men. The figures for modified
Framingham score were 39% and 35%, respectively.
Also, as an example, the D statistic was 1.79 (1.77 to
1.82) in women and 1.62 (1.59 to 1.64) in men for the
QRISK2 model compared with 1.63 (1.61 to 1.66) and
1.50 (1.47 to 1.52) for the modified Framingham score.
All threescoresperformedbetter inwomenthan inmen.
Figure 2 compares predicted and observed risks of a
cardiovascular disease event at 10 years across each
10th of predicted risk (first 10th representing the lowest
risk). This shows that the QRISK2 model is better
calibrated than the modified Framingham score.
Predictions with age, sex, deprivation, and ethnicity
Table 7 shows the breakdown of patients by age and
sex with a predicted 10 year risk of 20% or more with
the QRISK2 model and the modified Framingham
score. Overall, the QRISK2 model would predict
10.4% of patients as high risk comparedwith 14.9% for
the modified Framingham score.
Figure 3 shows the proportion of patients estimated
to be at high risk with QRISK2 and the Framingham
score within each ethnic group. QRISK2 would
identify 14.2% (11.5% to 17.0%) of Bangladeshi and
10.1% (8.8% to 11.3%) of Indian women at high
estimated risk compared with 7.2% (5.1% to 9.3%) and
4.6% (3.7% to 5.5%) with the Framingham score,
respectively. QRISK2 would identify 14.0% (13.9% to
Table 2 | Crude and age standardised cardiovascular disease incidence rate per 1000 person years with 95%confidence intervals by age, sex, deprivation,
and ethnicity in derivation dataset
Women Men
Total person
years
No of
incident
cases
Crude
incidence rate
Age standardised rates
(95% CI)
Total person
years
No of
incident
cases
Crude
incidence
rate
Age standardised rates
(95% CI)
Total 5 645 105 41 042 7.27 — 5 280 571 55 667 10.54 —
Age (years):
35-44 1 902 715 2590 1.36 — 1 971 609 5472 2.78 —
45-54 1 648 885 6823 4.14 — 1 621 901 13 076 8.06 —
55-64 1 192 905 12 438 10.43 — 1 047 287 18 281 17.46 —
65-74 900 599 19 191 21.31 — 639 775 18 838 29.44 —
Ethnic group:
White/not
recorded
5 537 244 40 278 7.27 7.25 (7.18 to 7.32) 5 190 709 54 705 10.54 10.53 (10.44 to 10.62)
Indian 21 654 186 8.59 10.88 (9.23 to 12.52) 20 150 285 14.14 16.88 (14.84 to 18.91)
Pakistani 10 981 115 10.47 13.24 (10.63 to 15.85) 9726 175 17.99 20.94 (17.75 to 24.13)
Bangladeshi 6707 67 9.99 11.30 (8.46 to 14.14) 5976 119 19.91 24.43 (19.83 to 29.03)
Other Asian 8097 45 5.56 8.41 (5.55 to 11.27) 5725 75 13.10 15.44 (11.84 to 19.03)
Black
Caribbean
25 126 209 8.32 9.72 (8.35 to 11.09) 18 888 141 7.46 7.02 (5.80 to 8.24)
Black African 12 869 33 2.56 3.78 (2.25 to 5.31) 11 014 44 3.99 6.21 (4.12 to 8.30)
Chinese 5863 18 3.07 4.92 (2.52 to 7.31) 4585 17 3.71 5.40 (2.51 to 8.29)
Other 16563 91 5.49 8.43 (6.56 to 10.29) 13 798 106 7.68 10.27 (8.26 to 12.27)
Fifth of Townsend deprivation score:
1 1 487 418 8488 5.71 6.01 (5.88 to 6.13) 1 374 821 13 181 9.59 9.43 (9.27 to 9.59)
2 1 283 177 7972 6.21 6.43 (6.29 to 6.57) 1 186 443 11 845 9.98 9.89 (9.72 to 10.07)
3 1 148 111 8599 7.49 7.35 (7.19 to 7.50) 1 060 665 11 456 10.80 10.70 (10.51 to 10.90)
4 970 900 8709 8.97 8.57 (8.39 to 8.75) 900 720 10 381 11.53 11.61 (11.39 to 11.83)
5* 755 499 7274 9.63 9.60 (9.38 to 9.82) 757 923 8804 11.62 12.38 (12.13 to 12.64)
*Most deprived.
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14.1%) of white men at high risk compared with 22.0%
(21.9% to 22.1%) with the Framingham score.
Reclassification statistics
Of the 112 156 patients classified as high risk (risk of
≥20% over 10 years) with the Framingham score,
46 094 (41.1%) would be reclassified at low risk with
QRISK2. The 10 year observed risk among these
reclassified patients was 16.6% (16.1% to 17.0%)—that
is, below the 20% threshold for high risk.
Of the 78 024 patients classified at high risk with
QRISK2, 11 962 (15.3%) would be reclassified as low
risk with the Framingham score. The 10 year observed
risk among these patients predicted to be at high risk
with QRISK2 was 23.3% (22.2% to 24.4%)—that is,
above the 20% threshold for high risk.
The annual incidence rate of cardiovascular events
among those with a QRISK2 score of ≥20% was 30.6
per 1000 person years (95% confidence interval 29.8 to
31.5) for women and 32.5 per 1000 person years (31.9
to 33.1) for men. Both these figures are higher than the
annual incidence rate for patients identified as high risk
with the modified Framingham score. The annual
incidence rate for these patients was 25.7 per 1000
personyears (25.0 to 26.3) forwomenwith 26.4 (26.0 to
26.8) formen. In otherwords, at the 20% threshold, the
population identifiedbyQRISK2wasat higher riskof a
CV event than the population identified by the
Framingham score.
Clinical examples
Table 8 shows someclinical examples forpatients from
different ethnic groups who would be reclassified with
QRISK2 compared with the modified Framingham
score. We have calculated 95% confidence intervals
around the QRISK2 score. For example, a 64 year old
Indianwoman from amoderately deprived area with a
systolic blood pressure of 130, BMI of 23.1, treated
Table 3 | Characteristics of first cardiovascular events in
derivation and validation cohort. Figures are numbers of
events (percentage of stroke or transient ischaemic attacks)
Ethnicity Derivation cohort Validation cohort
Women
White/not recorded 40 278 (35.3) 17 677 (34.8)
Indian 186 (21.0) 112 (23.2)
Pakistani 115 (18.3) 76 (34.2)
Bangladeshi 67 (31.3) 36 (19.4)
Other Asian 45 (28.9) 26 (26.9)
Black Caribbean 209 (33.5) 73 (42.5)
Black African 33 (24.2) 32 (40.6)
Chinese 18 (11.1) 14 (57.1)
Other 91 (31.9) 55 (29.1)
Men
White/not recorded 54 705 (27.6) 24 626 (27.2)
Indian 285 (19.6) 186 (22.6)
Pakistani 175 (16.6) 115 (20.9)
Bangladeshi 119 (13.4) 83 (16.9)
Other Asian 75 (20.0) 56 (23.2)
Black Caribbean 141 (48.9) 78 (35.9)
Black African 44 (36.4) 43 (27.9)
Chinese 17 (23.5) 13 (46.1)
Other 106 (24.5) 95 (28.1)
Table 4 | Distribution of cardiovascular disease risk factors by ethnic group in men and women in derivation cohort; figures are age standardised
Means Percentages
Age at
entry
Townsend
score
Systolic
blood
pressure BMI
Total
cholesterol/
HDL ratio
Family
history
of CHD
Current
smoker
Treated
hyperten-
sion
Type 2
diabetes
Rheumatoid
arthritis
Atrial
fibrillation
Chronic
renal
disease
Women
White/not recorded 54 −0.65 133 26.1 3.9 12.7 25.4 7.0 1.5 0.9 0.4 0.2
Indian 50 1.06 130 26.4 4.0 18.5 8.1 9.6 11.7 1.3 0.2 0.2
Pakistani 49 2.58 129 28.4 4.3 12.1 5.8 7.7 14.2 1.4 0.4 0.5
Bangladeshi 49 5.77 126 26.1 4.6 6.3 12.8 9.5 14.4 0.9 0.2 0.3
Other Asian 49 2.09 130 25.4 4.0 11.2 10.5 9.6 7.1 0.4 0.2 0.4
Black Caribbean 51 3.66 136 28.7 3.5 9.1 15.9 24.8 10.3 1.0 0.2 0.3
Black African 48 4.19 138 29.4 3.6 4.5 4.4 17.3 6.8 0.3 0.2 0.1
Chinese 49 1.95 125 23.4 3.7 6.2 6.1 9.8 5.2 0.8 0.1 0.4
Other 49 2.80 131 27.0 3.8 11.3 18.2 13.6 6.4 1.0 0.1 0.4
Men
White/not recorded 52 −0.5 136 26.6 4.5 9.7 32.2 5.5 2.1 0.4 0.6 0.1
Indian 48 1.1 133 25.7 4.6 16.8 23.7 12.0 13.3 0.4 0.3 0.4
Pakistani 48 2.6 131 26.3 4.9 13.0 32.9 5.7 12.0 0.2 0.2 0.2
Bangladeshi 48 5.5 126 25.0 5.2 5.9 53.2 6.4 16.8 0.8 0.1 0.2
Other Asian 48 2.2 132 25.5 4.7 9.1 28.3 8.3 10.3 0.2 0.3 0.1
Black Caribbean 53 3.7 136 26.7 3.9 6.4 40.6 14.0 9.0 0.3 0.3 0.4
Black African 47 4.3 139 26.6 4.0 3.2 16.6 15.6 8.6 0.3 0.3 0.6
Chinese 50 2.5 127 24.0 4.3 4.2 28.0 6.1 3.8 0.0 0.3 0.3
Other 49 3.0 134 26.5 4.4 8.5 34.4 9.3 7.9 0.4 0.3 0.3
BMI=body mass index; HDL=high density lipoprotein cholesterol; CHD=coronary heart disease.
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hypertension, and cholesterol/HDL ratio of 5.3 would
have a modified Framingham score of 12.0%, but a
QRISK2scoreof 24.7% (24.4% to25.0%) at 10years.A
54 year old Bangladeshi manwho is a non-smoker and
has treated hypertension, a systolic blood pressure of
142mmHg,aBMIof27.0, andacholesterol ratioof4.2
and lives in one the most deprived areas would have a
modified Framingham score of 17.0% (including the
adjustment for being south Asian) but a 10 year
QRISK2 score of 23.5% (22.8% to 24.1%).
DISCUSSION
We developed and validated a cardiovascular risk
algorithm that simultaneously takes account of ethni-
city and deprivation. The algorithm has face validity in
the setting in which it will be used and had good
discrimination and calibration. There are three main
reasons why this study is likely to make an important
impact on the decisions of doctors, patients, and
commissioners. Firstly, in this prospective study we
developed and validated a risk prediction algorithm
that provides an individualised estimate of cardio-
vascular risk and includes the independent contribu-
tions of ethnicity and deprivation. This permits
identification of those individuals and groups likely to
be most disadvantaged by use of existing treatment
algorithms. Such patients include south Asian women,
whowouldotherwisebe less likely tobe identified.This
information will, if acted on, help to reduce health
inequalities.
Secondly, it extends and improves on our original
equation for cardiovascular risk12 by incorporating
important additional clinical conditions (such as
rheumatoid arthritis, chronic kidney disease, and atrial
fibrillation), allowing more accurate quantification of
risks for individual patients. This information should
be considered in the context of specific treatment
guidelines. Knowledge of cardiovascular risk might be
useful in assessing response efficacy and concordance
with recommended healthcare interventions for these
specific conditions.
Thirdly, it also allows better quantification of risk of
cardiovascular disease for patientswith type 2diabetes,
which is especially prevalent among south Asian
patients. Though there are alternative cardiovascular
risk algorithms for patients with diabetes,18 48 none is
based on a large nationally representative primary care
cohort, has large numbers of incident events, and also
simultaneously takes account of other important risk
factors such as deprivation and ethnicity. Although
current guidelines might indicate statins for people
with diabetes, knowledge of cardiovascular risk can be
useful in helping to identify patients at particularly low
risk for whom a statin might not be needed.
Strengths and limitations
The strengths and limitations of using this approach
and the QRESEARCH database to develop and
validate a new risk prediction algorithm have been
discussed previously.12 27
We included more sophisticated modelling of the
effect of age on risk factors, which results in greater
weightingof some risk factors in younger patients, such
as smoking status, family history of coronary heart
disease, type2diabetes, systolicbloodpressure, treated
hypertension, BMI, deprivation, and atrial fibrillation.
This also has the effect that in people without the risk
factors the increase in risk with age will be steeper than
with QRISK1. The inclusion of patients with type 2
diabetes in themain study population will have tended
to increase the overall level of risk in the study
population and this will also have tended to increase
the risk for an individual, as canbe seen fromthehazard
ratios (table 5).
We updated the analysis to include data until March
2008, increasing the number of patients with at least
10 years of follow-up data to almost 440 000 patients.
We have furthermore included the linked cause of
death as recorded by the Office for National Statistics
(ONS).Death linkage increasedcasesof cardiovascular
disease by about 7% across the entire study period, as
Table 5 | Adjusted hazard ratios (95% CI) for cardiovascular disease for QRISK2 model in
derivation cohort (see figure 1 for effect of age on relevant hazard ratios where there are
age interactions)
Women Men
White/not recorded 1 1
Indian 1.43 (1.24 to 1.65) 1.45 (1.29 to 1.63)
Pakistani 1.80 (1.5 to 2.17) 1.97 (1.70 to 2.29)
Bangladeshi 1.35 (1.06 to 1.72) 1.67 (1.40 to 2.01)
Other Asian 1.15 (0.86 to 1.54) 1.37 (1.09 to 1.72)
Black Caribbean 1.08 (0.94 to 1.24) 0.62 (0.53 to 0.73)
Black African 0.58 (0.42 to 0.82) 0.63 (0.47 to 0.85)
Chinese 0.69 (0.44 to 1.10) 0.51 (0.32 to 0.83)
Other 1.04 (0.85 to 1.28) 0.91 (0.75 to 1.10)
Age (10% increase)* 1.66 (1.65 to 1.68) 1.59 (1.58 to 1.60)
BMI (5 unit increase) 1.08 (1.06 to 1.10) 1.09 (1.07 to 1.11)
Townsend score (5 unit increase) 1.37 (1.34 to 1.40) 1.18 (1.16 to 1.20)
Systolic blood pressure (mm Hg) (20 unit
increase)
1.20 (1.18 to 1.22) 1.19 (1.17 to 1.20)
Cholesterol/HDL ratio 1.17 (1.16 to 1.18) 1.19 (1.18 to 1.20)
Family history coronary heart disease 1.99 (1.92 to 2.05) 2.14 (2.08 to 2.20)
Current smoker 1.80 (1.75 to 1.86) 1.65 (1.60 to 1.70)
Treated hypertension 1.54 (1.45 to 1.63) 1.68 (1.60 to 1.77)
Type 2 diabetes 2.54 (2.33 to 2.77) 2.20 (2.06 to 2.35)
Rheumatoid arthritis 1.50 (1.39 to 1.61) 1.38 (1.25 to 1.52)
Atrial fibrillation 3.06 (2.39 to 3.93) 2.40 (2.07 to 2.79)
Renal disease 1.70 (1.43 to 2.03) 1.75 (1.51 to 2.02)
Age* BMI interaction 0.976 (0.970 to 0.982) 0.985 (0.979 to 0.991)
Age* Townsend interaction
(5 unit increase in score)
0.938 (0.930 to 0.946) 0.973 (0.967 to 0.98)
Age* systolic blood pressure interaction
(20 unit increase in systolic blood pressure)
0.966 (0.961 to 0.971) 0.964 (0.96 to 0.969)
Age* family history interaction 0.927 (0.914 to 0.94) 0.923 (0.912 to 0.935)
Age* smoking interaction 0.931 (0.920 to 0.943) 0.932 (0.922 to 0.942)
Age* treated hypertension interaction 0.952 (0.934 to 0.971) 0.916 (0.901 to 0.931)
Age* type 2 diabetes interaction 0.904 (0.877 to 0.931) 0.902 (0.881 to 0.924)
Age* atrial fibrillation interaction 0.858 (0.795 to 0.926) 0.893 (0.852 to 0.935)
BMI=body mass index; HDL=high density lipoprotein cholesterol.
*All age terms expressed as 10% increase in age (for example, 50 to 55 years).
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the data fromONSwere not available for the full study
period at the time of the original study.27
We used self assigned ethnicity as reported by the
patient to their general practice; this has advantages
over analyses where ethnicity is assigned by an
informant rather than the patient or is imputed
geographically or is related to country of birth. The
latter is particularly problematic with increasing
numbers of people from ethnic minorities now being
born in the UK.49 We also disaggregated the south
Asian groups and reported on them separately, which
addresses concerns with studies that tend to combine
them into one group when there are differences in
exposure to risk factors and rates and outcomes of
diseases.25 Though only a quarter of patients had self
assigned ethnicity recorded,we think it is reasonable to
assume that where patients have self assigned ethnicity
recorded as Bangladeshi (for example) that this is
accurate and the patient was indeed Bangladeshi.
Misclassification would most affect the reference
category of “white or not recorded,” but because of
the mix of the populations of England and Wales less
than 10% of such patients were probably from a non-
white ethnic group. This misclassification would
therefore, if anything, tend to underestimate the
relative effect of ethnicity on cardiovascular risk.
Just fewer than 3%of our total samplewere classified
as belonging to aminority ethnic group comparedwith
thenational proportion in this agegroupof 6.6% (based
on projections for 200650). The comparison, however,
is not “like for like” as national estimates are for 2006
and migration patterns and population demographics
have probably changed over the 15 year period of our
study. None the less, the lower percentage of patients
Table 6 | Validation statistics for newQRISK2model comparedwithmodifiedNICE equation in
validation cohort. Figures aremeans (95%confidence intervals)
QRISK2 model QRISK1 model
Modified Framingham
equation
Women
R2 43.47 (42.78 to 44.16) 42.94 (42.23 to 43.66) 38.87 (38.12 to 39.62)
D statistic 1.795 (1.769 to 1.820) 1.776 (1.750 to 1.801) 1.632 (1.606 to 1.658)
ROC statistic 0.817 (0.814 to 0.820) 0.814 (0.811 to 0.817) 0.800 (0.797 to 0.803)
Brier score 0.086 (0.083 to 0.089) 0.081 (0.078 to 0.084) 0.093 (0.090 to 0.096)
Men
R2 38.38 (37.75 to 39.01) 37.63 (36.99 to 38.27) 34.78 (34.12 to 35.45)
D statistic 1.615 (1.594 to 1.637) 1.590 (1.568 to 1.612) 1.495 (1.473 to 1.517)
ROC statistic 0.792 (0.789 to 0.794) 0.788 (0.786 to 0.791) 0.779 (0.776 to 0.782)
Brier score 0.136 (0.134 to 0.139) 0.128 (0.125 to 0.131) 0.177 (0.174 to 0.180)
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Fig 2 | Predicted and observed risk by 10th of predicted risk for QRISK2model and NICE modification of score in validation dataset
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from minority groups raises concerns about the
possible under-representativeness of practices from
ethnically diverse inner city areas or misclassification
error, or both. We think under-representativeness of
practices from ethnically diverse areas is unlikely as
QRESEARCH practices are drawn from across
England andWales and have been shown to be similar
to practices nationally for a rangeofmeasures.26 In fact,
QRESEARCH has proportionately more practices in
areas of higher ethnicity such as the East Midlands,
Yorkshire, and Humberside (fig 4. Also, table 1 shows
that among patients from both cohorts, when ethnicity
was recorded 11.7% were from a minority group. This
is higher than from census estimates for 2006,
indicating either over-representation of practices
from ethnically diverse areas or that practices in
ethnically diverse areas are more likely to record
ethnicity, or both. Therefore, the reason for the
apparent under-representation of people from black
and minority ethnic groups has arisen is probably
because we combined thenot recorded and the white
groups. This combined group will contain additional
patients fromgroups classified as other thanwhite.This
would, if non-differential, result in a bias towards the
null hypothesis of no difference in risk between ethnic
groups. The net consequence of this would be, if
anything, to underestimate hazard ratios in the
minority ethnic populations in question rather than
generate spurious associations.
With a number of policy and legislative drivers co-
aligning, ethnicity coding is likely to improve expo-
nentially in the UK, and this evolving picture will
therefore allow us to continue tomonitor the impact of
incorporating more complete ethnicity data into our
models. But for the present, even though it is imperfect,
incorporating ethnicity into our disease risk algorithm
has, we believe, clearly been an important advance in
understanding risk of disease in ethnically diverse
populations. Furthermore, it is unlikely that a better
estimate could be obtained for England and Wales
given the difficulties of assembling a sufficiently large
prospective cohort for follow-upover10ormoreyears.
Another potential limitation of our study is that we
have assumed that the absence of a recorded diagnosis
of diabetes (or family history, for example) is equiva-
lent to the person not having that factor. This is
probably valid for diabetes as there have been
consistent efforts in general practice over the past
15 years to develop and validate diabetes registers
(including comparisons against prescribed medication
for diabetes), though we accept there will additionally
be large numbers of cases not yet diagnosed by
clinicians.Recordingof familyhistory is less systematic
in primary care and might be more susceptible to
recording bias. As recording of risk factors becomes
more complete over time, then better estimates of the
relevant hazard ratios will be possible.
Also relevant is that we have calculated 95%
confidence intervals around the QRISK2 scores to
give a better idea of precision. We have improved on
themethod for validationbyusingmultiple imputation
formissingvalues in thevalidation set rather thanmean
values by age and sex derived from the derivation
dataset as in our original study and independent
validation.12 27 One important limitation, though, is
that while we have validated the results in a physically
discrete group of practices, these practices all use the
same EMIS clinical system and hence there is a
potential “home advantage” that might reduce the
generalisability to other systems, although, conversely,
it is ideally suited for use in the EMIS system. In other
words, any comparison done in the one third sample of
practices in QRESEARCH will tend to favour
QRISK2 compared with other prognostic scores. Our
previous study27 was additionally validated in a
database (THIN, “The Health Improvement
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Network”) derived from a set of practices using a
different clinical system (In Practice Systems) and gave
similar results (apart from the prevalence of family
history, which was lower in the THINdatabase). This
suggests that our findings are probably generalisable to
the 20% of practices in England andWales that use In
Practice Systems in addition to the 60%ofpractices that
already use the EMIS clinical system from which the
equation is derived. Further validation of QRISK2 is
not currently possible on the THIN database as the
database does not have the linked ONS death
certificate data and recording of ethnicity is too low
(personal communication, THIN, 2008). The valida-
tion we have presented constitutes the best currently
possible given the extent and nature of comparable
datasets. The results should generalise to at least 80%of
practices nationally. None the less, it is important that
QRISK2 is validated by another team on external
populations and an international version ofQRISK2 is
being developed to allow this and will be reported in
due course. In particular, we are working with another
primarycaredatabase (THIN) to link their data toONS
death certificate data so that this can be used as a data
source for further validation. Ethnicity recording could
be improved on primary care databases by linkage of
individual level data on self assigned ethnicity from the
2001 census, and this will be undertaken and reported,
assuming access to these data is granted.
Comparisons with the modified Framingham score
This study improves on our original equation for
cardiovascular risk in terms of its potential application
as outlined above and also because the more complex
model has slightly better discrimination (that is, greater
ability to separatepatients at highand lowrisk) thanour
original model. The QRISK1 equation improved on
other equations in use in the UK by including
additional readily available risk factors such as
deprivation, family history, BMI, and blood pressure
treatment. With QRISK2, the improvement in dis-
crimination and calibration compared with the mod-
ified Framingham score remains significant, although
this is probably partly because the modelling was
undertaken on a more contemporaneous population
from England and Wales and we used a more
sophisticated approach for modelling and included
additional variables. We have not compared QRISK2
with themost recently published Framingham score as
this uses a much broader definition of cardiovascular
disease that is less relevant toUKguidelines.51QRISK2
seems to improve on the Framingham score based
Ethrisk,19 perhaps because of its greater precision,
larger sample, and prospective study design.
In contrast to our previous study, we compared
QRISK2 with the modified Framingham risk score
recently recommended by NICE. Themodified score,
in common with the risk equation advocated by the
Joint British Societies, involves summing risks from
two risk equations for coronary heart disease and
stroke, which is mathematically incorrect because
these are not independent outcomes and therefore
will give an invalid result. This addition of the two
separate and non-independent risks results in some
patients having an estimated risk of more than 100%
andwould also result in overestimation of risk for other
individuals at lower estimates of risk. This might have
accounted for someof theoverprediction.The inflation
factors of 1.4 for southAsianmenand1.5 for thosewith
a family history coronary heart disease, which have
been developed by consensus rather than a mathema-
ticalmodel based on individual patient data,might also
have accounted for some of the overprediction,
although this was still present on our previous analysis
where the inflation factors had not been applied.12 27
Comparisons with the literature
We found substantial heterogeneity between risk
factors within south Asian populations and our
prevalence figures for risk factors are comparable
with the literature,19 20 which increases the face validity
of our findings. For example, as others have found,
Bangladeshi men have higher rates of smoking but
lower mean systolic blood pressure levels than
Pakistani or Indian men.20 Indian and Pakistani men
and women have higher mean BMI than
Bangladeshis.20 Prevalence of type 2 diabetes was
higher in Bangladeshis and Pakistanis than Indians.20
Similarly, cholesterol/HDL ratio was higher among
each of the south Asian groups compared with the
white reference category.20 Our findings also confirm
Table 7 | Numberandpercentageofpatientsinvalidationcohort
with estimated cardiovascular risk of ≥20%by five year age
bandwithQRISK2 comparedwithmodified Framingham
equation
Age (years)
Total
population
QRISK2 model
(%)
Modified
Framingham
equation
Women
35-39 78 887 16 (0.02) 4 (0.01)
40-44 62 153 56 (0.09) 88 (0.14)
45-49 55 879 193 (0.35) 636 (1.14)
50-54 49 392 517 (1.05) 2048 (4.15)
55-59 40 183 1228 (3.06) 3892 (9.69)
60-64 33 831 2971 (8.78) 5952 (17.59)
65-69 29 045 6657 (22.92) 7870 (27.10)
70-74 26 393 13 988 (53.00) 9581 (36.30)
Men
35-39 85 424 97 (0.11) 289 (0.34)
40-44 67 911 345 (0.51) 1570 (2.31)
45-49 58 085 910 (1.57) 4703 (8.10)
50-54 49 171 2336 (4.75) 9635 (19.59)
55-59 38 955 4986 (12.90) 14 330 (36.79)
60-64 30 849 9649 (31.28) 17 008 (55.13)
65-69 24 924 15 905 (63.81) 18 117 (72.69)
70-74 19 150 18 170 (94.88) 16 433 (85.61)
Totals
Women 375 763 25 626 (6.82) 30 071 (8.00)
Men 374 469 52 398 (13.99) 82 085 (21.92)
Both 750 232 78 024 (10.40) 112 156 (14.95)
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 11 of 15
Nazroo’s observations52 and the findings of theWhite-
hall II study53 of the independent effects of both
ethnicity and deprivation. Overall, the results of our
study add to a growing body of evidence that
combining people of south Asian origin into one
category is potentially misleading.
The magnitude of the increased cardiovascular risk
among south Asians compared with white patients
seems to be higher than the 40% previously thought in
the absence of prospective incidence data.22 24 For
example, in our study, compared with the white
reference group the adjusted risk is 45% higher (29%
to 63%) among Indianmen, 67% higher (40% to 101%)
among Bangladeshi men, and 97% higher (70% to
129%) among Pakistani men, even after adjustment for
multiple confounders including deprivation and dia-
betes. Similarly, the adjusted risks for Indian,Pakistani,
and Bangladeshi women are all increased compared
with the white reference population. Our results also
suggest that the increased cardiovascular risks
observed for Pakistani men are significantly higher
than those for Indian men. The difference between
these two groups for women is similar, although of
borderline significance when a direct comparison is
made, probably because of a lack of power.
There were also differences in the proportion of
events that were stroke or transient ischaemic attacks
rather than coronary heart disease. For example, a high
proportion of first events among black Caribbean and
blackAfricanswas stroke or transient ischaemic attacks,
which is consistent with the literature.5455 Other studies
have found differences in mortality between different
ethnic groups, such as the unexplainedpersistent higher
mortality among Bangladeshis.56 This deserves further
study as to the underlying causes and potential missed
opportunities for care.
Clinical implementation
QRISK2 has been designed to estimate cardiovascular
risk for an entire population of patients in primary care
by using data already collected within the patient’s
electronic health record and by using default values for
body mass index, cholesterol concentration, and
systolic blood pressure where these data have not
been recorded in the past five years. Computer
generated risk scores have been integrated within
routine clinical use of computers in UK primary care
for the past 10 years, and, with QRISK2 embedded
within computer applications, a rank ordered recall list
can be generated so that those at greatest clinical need
can be recalled first. Once such patients have been
recalled, the individual can have a full clinical cardio-
vascular check to calculate an actualQRISK2based on
the most up to date data that are then used to guide
decisions about treatment.
The only item in QRISK2 that is not already
routinely collected and recorded electronically is the
Townsend deprivation score, which is linked to an
individual postcode. This score has already been
integrated into the EMIS clinical system and linked to
the records of over 32million patients. Themapping of
postcode to deprivation score will also be made
available, togetherwith the supporting reference tables
and algorithm itself. QRISK2 can then be integrated
within clinical management systems so that it can be
usedonanongoingbasis to generate anestimated score
based on existing data. QRISK2 will be updated as
improved analytical techniques are developed for
application to the QRESEARCH database. QRISK
will evolve as data quality and completeness improves
and population characteristics change (obesity is
increasing, while incidence of cardiovascular, for
example). This will ensure that future versions of
QRISK remain well calibrated to the population of
England and Wales and makes best use of technical
developments. Lastly, the NHS’ electronic health
record(NHS Care Record Service) is central to the
NHSConnecting forHealth’s national programme for
information technologyand thiswill,withina relatively
short space of time, result in electronic health records
replacing paper based records in hospitals in
England.57 The plan is for these eventually to
incorporate computerised decision support tools and
so this will allow disease risk algorithms such as
QRISK2 to be largely automatically populated with
routine electronically coded data as is already possible
in primary care in the UK.
These estimates, like any predictive score, are an aid
but not a replacement for judgment in individual
clinical circumstances. We have specifically identified
atrial fibrillation and rheumatoid arthritis for consid-
eration as both are known to be associated with
increased risk31 32 58 59 and knowledge of them might
inform clinical management for an individual patient.
We recognise that the likely age and comorbidity of
these individuals, however, might place them at being
at high risk of cardiovascular disease and therefore not
appropriate for a primary prevention tool such as
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Fig 4 | Proportion of practices in England by geographical region in national attribution dataset
(Department of Health) and in QRESEARCH on 31 March 2004
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QRISK2. Nevertheless, if we had omitted rheumatoid
arthritis and atrial fibrillation, the effect would be to
underestimate risk for individuals with either of these
two conditions who did not yet have concurrent
cardiovascular disease. The prevalence of rheumatoid
arthritis and atrial fibrillation is low so this will have a
minimal impact on the overall precision of the model
or its application at a population level, but we believe
the additional complexity of themodel is justified as no
additional data entry will be required frommost users,
while it also provides relevant information to the
individual patientwith one or either of these conditions
and their clinicians.
QRISK2 provides a mechanism for estimating
absolute risk among individuals. Use of this informa-
tion, however, should be tightly coupled with suitable
guidelines. There are some patients in whom a
QRISK2 score should not be calculated, including
those with pre-existing cardiovascular disease (whowe
excluded from this study). Risk estimation should not
be used for people with conditions such as peripheral
vascular disease, heart failure, familial hypercholester-
olaemia, or other conditions not specifically identified
in the algorithm that are known to be associated with
high risks of cardiovascular events.5 We have not
added further to the exclusions in this dataset as todo so
would have added complexity with no appreciable
gain in precision for people in whom we do not
recommend the use of this score.
Clinical impacts and health inequalities
A risk prediction algorithm that does not include
deprivation or ethnicity is likely to result in the
inequitable definition of risk for affluent and deprived
communities and also substantially underestimate the
risk in southAsianpeople, especiallywomen, inwhom,
likemen, it is the commonest causeof prematuredeath.
Primary prevention programmes that do not take these
variables into account risk exacerbating rather than
reducing existing health inequalities,6-8 especially as
the evidence suggests that health inequalities naturally
widen at the start of new health initiatives.21 Other
research highlights additional difficulties with acces-
sing effective health promotion, including lack of risk
awareness, influences of culture and lifestyle, time
restrictions, and languagedifficulties60 and this needs to
be addressed once patients have been identified to
improve clinical outcomes.
The QRISK2 algorithm, like its predecessor, has
better calibration and is a better discriminator of risk of
cardiovascular disease than the modified Framingham
score. A major advantage of QRISK2 is the ability of
the algorithm to be updated as population demo-
graphics, ethnic composition, prevalence of risk
factors, and incidenceof cardiovasculardiseasechange.
It also demonstrates the utility of linked electronic data
for research to develop tools that can help doctors to
make better decisions. The marked gradient with
deprivation has already been demonstrated with
QRISK1. The further identification of ethnicity as an
independent factor additional to deprivation is an
important consideration, particularly for south Asian
women at high risk. A broader range of important
clinical conditions included in QRISK2 but not in the
modified Framingham score make it a more clinically
relevant tool. Highlighting risks of conditions includ-
ing type 2 diabetes and chronic renal disease supports
further integration of vascular strategies and informs
individual assessment.
The modified Framingham score underestimates
risk in south Asian women. Like the earlier version,
QRISK2 includes BMI and treatment for hyperten-
sion, neither of which are included in the Framingham
score; in QRISK2, family history contributes an
important additional weighting particularly at younger
ages. The clinical relevance, superior performance,
and equitable assignment of QRISK2 make it an
appropriate tool to assist in thedeliveryofpublic health
Table 8 | Clinical examples for patientswhowould be reclassifiedwithQRISK2 instead of NICEmodified Framinghamequation
Age (years) Ethnic group
Family
history
Systolic
blood
pressure BMI
Choles-
terol/HDL
ratio Smoker
Treated
hyperten-
sion
Type 2
diabetes*
Chronic
kidney
disease
Townsend
score†
Framing-
ham score
10 year
risk (%)
QRISK2 10 year risk
(%) (95% CI)
Men
65 Indian Yes 100 24.7 3.3 No No No No 5 17 31.3 (30.9 to 31.7)
54 Bangladeshi No 142 27.0 4.2 No Yes No No 10 17 23.5 (22.8 to 24.1)
54 Black African No 150 21.0 7.3 No No No No 4 23 9.0 (7.7 to 10.3)
55 Indian No 156 27.0 4.7 No No No No −4 24 12.7 (12.2 to 13.2)
65 Caribbean No 146 29.1 5.4 No No No No 4 26 14.8 (14.2 to 15.5)
42 White Yes 132 36.0 5.3 Yes Yes No No 11 17 35.2 (34.9 to 35.5)
Women
64 Indian No 130 23.1 5.3 No Yes No No 5 12 24.7 (24.4 to 25.0)
60 Bangladeshi No 132 36.0 4.3 No Yes No No 11 9 21.1 (20.6 to 21.6)
48 Pakistani Yes 140 33.2 4.5 No Yes No No 8 9 26.1 (25.7 to 26.4)
58 White No 154 34.0 3.4 Yes Yes No No 10 16 21.4 (21.3 to 21.5)
BMI=body mass index; HDL=high density lipoprotein cholesterol.
*NICE lipid modification guideline does not include diabetes so this is for illustrative purposes only.
†Interval score ranges between −6 (most affluent) and 11 (most deprived).
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programmes that recognise the broader determinants
of cardiovascular health, such as ethnicity and depriva-
tion. This has particular relevance to equity of delivery
of health care to the UK’s south Asian communities
andmight help to reduce widening health inequalities.
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